Foghorn Therapeutics stockholders elect four Class II directors, ratify Deloitte as auditor

Foghorn Therapeutics Inc.

Elected Stuart Duty, Neil J. Gallagher, Adrian Gottschalk, and Ian F. Smith as Class II directors for three-year terms.
Votes for nominees ranged from 30.9M (Ian F. Smith) to 34.6M (Neil J. Gallagher); 8.68M broker non-votes.
Ratified Deloitte & Touche LLP as independent auditor for FY2025 with 43.34M votes for, 16,978 against.
Total shares present at meeting: 43,369,822 out of 55,721,340 outstanding; all proposals approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.